Physician profile
Alan Maloon
NPI 1093808057
$73,564.15
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $31K · 2021: $24K · 2022: $16K · 2023: $218 · 2024: $33.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25,215.16 | 2019-2022 | |
| Abbvie INC. | $20,894.01 | 2021-2024 | |
| Allergan, INC. | $20,377.91 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $2,576.75 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $1,137.95 | 2019-2022 | |
| Ucb, INC. | $410.12 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $321.23 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $310.45 | 2022-2023 | Trudhesa |
| Zyla Life Sciences, INC. | $230.98 | 2019-2020 | |
| Biogen, INC. | $200.82 | 2020-2022 | |
| Amgen INC. | $193.94 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $190.87 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $186.11 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $175.01 | 2022 | |
| Neurelis, INC. | $144.55 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Maloon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.